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Abstract
The number of patients requiring cardiovascular implantable electronic device (CIED,
e.g., pacemaker and defibrillator) surgery is increasing rapidly and at least a quarter of
them are using chronic oral anticoagulation (OAC). Recently, the traditional approach
of withholding anticoagulation and using heparin bridging has been challenged by
studies showing safety of performing CIED surgery under anticoagulation with vitamin
K antagonists. Bridging with heparin is associated with incremental healthcare costs,
prolonged hospital  admission, and also with an augmented relative risk of pocket
hematoma. The risk of embolic events seems to be low and similar with the use of two
strategies  (heparin bridging and continuous warfarin).  Experience with novel  oral
anticoagulants is limited. Few studies suggest that withholding 48–72 hours before
surgery and performing the procedure under anticoagulation are safe alternatives.
However, larger randomized clinical trials are needed before definitive conclusions. In
this chapter, we review the management of anticoagulation around cardiac implanta‐
ble electronic device surgery under new conditions.
Keywords: cardiac resynchronization therapy, implantable cardiac defibrillator, unin‐
terrupted warfarin
1. Introduction
Each year, around 1.25 million pacemakers and 410,000 implantable cardioverter defibrillators
(ICDs) are implanted worldwide. It is estimated that 25–35% of patients undergoing cardiac
implantable electronic device (CIED) surgery receive long-term oral anticoagulation (OAC).
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Many patients are also receiving oral antiplatelet therapy for primary or secondary cardio‐
vascular events [1] and are exposed to an increased risk of bleeding during the perioperative
period.
Pocket hematoma formation is the most common complication of CIED implantation [2].
Although benign in most cases, it can have serious consequences, such as prolongation of
hospitalization, need for further surgery, and an increased risk of infection.
The periprocedural management of OAC poses a challenge, particularly in patients with
moderate or higher risk (>5%/y) of arterial thromboembolic events (ATEs). Subtherapeutic
anticoagulation exposes patients with atrial fibrillation (AF) to potential thromboembolic
complications, with a calculated daily risk ranging from 0.01 to 0.05% [3]. Heparin is expected
to reduce venous and arterial thromboembolism by 66–80% [4], but is associated with an
increased risk of pocket hematoma.
Conversely, subtherapeutic anticoagulation exposes patients with AF to potential throm‐
boembolic complications, with a calculated daily risk ranging from 0.01 to 0.05% [3]. This
dilemma led some centers to perform this type of procedure without interrupting the OAC in
patients deemed to be at a high risk for thromboembolic events.
2. Strategies for management of anticoagulation around CIED surgery
There are three perioperative anticoagulation strategies that can be employed:
1. Uninterrupted warfarin.
2. Withholding warfarin without bridging.
3. Withholding warfarin with perioperative bridging using heparin.
Theoretically, each strategy has its own advantages and limitations. The traditional strategy
is to withhold warfarin with perioperative bridging using heparin in high-risk patients. This
approach was linked to potential complications: a high risk of hematoma (between 17 and
31%), increased duration and costs of hospital stays, and increased risk of reoperation [5].
In a meta-analysis, we compared uninterrupted warfarin versus bridging using heparin.
Maintenance of OAC, when compared to heparin bridge with unfractionated heparin or
enoxaparin, had a lower risk of perioperative bleeding (OR = 0.25, 95% CI 0.17–0.36, P < 0.00001)
(Figure 1). The risk of ATE was very low in our study, with only three events occurring in the
group that received uninterrupted warfarin and one event in the group that received heparin
bridging (OR = 1.86; 95% CI, 0.29–12.17; P = 0.57) [6].
Particularly, in the BRUISE study, thromboembolic events occurred in patients who were
under OAC, but with INRs below the therapeutic range at the time of the event. Therefore,
risk is probably more related to the adequacy of the anticoagulation control rather than the
strategy applied.
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Importantly, device pocket hematomas can necessitate prolonged cessation of anticoagulation
with the attendant risk of ATE [6, 7]; they can significantly increase the duration and cost of
hospitalization; and sometimes reoperation is required. Uslan et al. [8] have also highlighted
the strong link between pocket hematoma and reintervention, the latter is an independent
predictor of ICD infections.
Proietti et al. [9] found similar results in a meta-analysis with similar design that included 15
studies. Heparin bridging was associated with an increased risk of bleeding (OR = 4.47; 95%
CI, 3.216.23; P < 0.00001), and prolonged hospital stay (9.13 ± 1.9 days vs. 5.11 ± 1.39 days; P <
0.00001). Adding heparin decreased the risk of ATE when compared with no anticoagulation
(0.50% vs. 1.07%, P = 0.02), but there was no difference when heparin was compared with
continuous OAC (P = 0.83). Results from this study discourage adoption of a strategy of OAC
suspension with no heparin bridging.
Figure 1. Risk of pocket hematoma in patients with oral anticoagulation continuation versus heparin bridging therapy,
according to study design. Random effect model.
The BRIDGE study was a large randomized trial that compared bridging with low-molecular-
weight heparin or placebo in patients anticoagulated with warfarin undergoing different types
of surgeries [10]. Warfarin treatment was stopped 5 days before the procedure and was
resumed within 24 hours after the procedure. During these periods, patients received low-
molecular-weight heparin or placebo. Both groups had a similar low risk of ATE (0.4% in the
no-bridging group and 0.3% in the bridging group). The incidence of major bleeding, however,
was lower in the no-bridging group (relative risk, 0.41; 95% CI, 0.20–0.78; P = 0.005 for
superiority).
This study included patients with low- to moderate-risk ATE—with a mean CHADS2 score
of 2.3 and no mechanical heart valves. Studies during the perioperative period of CIED surgery
included patients with moderate- to high-risk ATE. Also, CIED surgery represents a different
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scenario in which bleeding rarely is life threatening and is simple to diagnose. Therefore, we
do not believe that results from BRIDGE should be applied to CIED surgery with the possible
exception of patients with low risk of ATE.
The increased risk of bleeding related to heparin bridging has multiple causes. Feng et al. [11]
hypothesize that the variations on the accuracy of monitoring of warfarin compared with
heparin can partially explain differences in the observed risk of bleeding. Activated partial
thromboplastin time (APTT) levels of 1.5–2.5 time control do not correlate well with the
intensity of anticoagulation and have not been validated by randomized studies [12]. More‐
over, heparin has antiplatelet effects that may last longer than the measurable effect of heparin
and APTT [13]. Meanwhile, the evidence to maintain a therapeutic INR during the procedure
is based on more consistent data of cohorts and randomized trials [14, 15]. Performing surgery
under anticoagulation can facilitate the detection of small bleedings during the procedure [16].
This allows surgeons to make the necessary interventions at the time of the procedure and
potentially reduce the risk of hematoma in the postoperative period. This phenomenon has
been referred to as an “anticoagulation stress test.”
Figure 2 shows a simplified guide for management of patients using OAC with vitamin K
antagonists and requiring CIED surgery.
Figure 2. Guide for management of patients using OAC with vitamin K antagonists and requiring CIED surgery.
2.1. Role of novel anticoagulants
The use of novel anticoagulants (NOACs) has increased dramatically since its introduction
with about 1/3 of patients with AF using them for stroke prophylaxis [17]. They represent a
safe and efficacious alternative to warfarin. However, unlike warfarin, NOACs have a
predictable dose-response curve. When prescribing these drugs, there is no need to monitor
the INR levels to achieve therapeutic doses.
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All NOACs are at least noninferior to warfarin in terms of efficacy for prevention of stroke in
patients with nonvalvular AF [18–20]. In the same population, they are also at least as safe as
warfarin in terms of major bleeding. NOACs are also at least as effective and as safe as warfarin
for the treatment of venous thromboembolism [21, 22]. In patients with mechanical heart
valves, dabigatran was inferior to warfarin in terms of stroke prevention and bleeding risk [23];
therefore, the use of NOAC was contraindicated in this population.
However, recommendations for periprocedural use of NOAC are not well established as they
pose particular challenges:
1. Number of agents available on the market—dabigatran, rivaroxaban, apixaban, and
edoxaban—each one with a unique pharmacokinetic profile.
2. Unavailability of an efficacious and widespread antidote in the case of urgent need to
reverse anticoagulation.
3. Unavailability of a reliable laboratory test to measure the anticoagulation effect.
Some authors recommend that in patients with an annual risk of ATE (>5%), NOAC could be
resumed 24 hours after surgery. In patients with a lower risk of ATE (<5%), it would seem
reasonable to wait for >48 hours after surgery [24, 25].
Randomized trials like the planned BRUISE CONTROL-2 trial, which will compare continued
vs. interrupted novel oral anticoagulant (dabigatran, rivaroxaban, or apixaban) at the time of
device surgery [23], will bring more definitive answers.
In cases of clinical significant bleeding and need of urgent reversal of anticoagulation, several
strategies have been studied and proposed in this setting. Mar et al. [26] suggest that if criteria
for activated charcoal or hemodialysis use are not met, the use of four-factor prothrombin
complex concentrate (25 U/kg, maximum dose of 2500 U) may be attempted to reverse
dabigatran, as well as rivaroxaban and apixaban. Recently, a novel recombinant human factor
Xa, andexanet alfa (AnXa), that binds with high affinity to apixaban and rivaroxaban has
showed promising results in phase 3 studies [27].
Until more conclusive results are published, we recommend withholding NOAC four half-
lives before elective procedures and restart the drug as soon as the risk of bleeding is mini‐
mized.
2.2. Cost-effectiveness
Bridging therapy is associated with increased costs due to increased need for hospitalization
and the high price of LMWH [27]. In the BRUISE CONTROL STUDY, the overall cost of
continued warfarin therapy was dramatically lower than heparin bridging therapy, primarily
due to lower costs for medication and hospitalizations [28]. From the perspective of the
Canadian healthcare system, continued warfarin therapy, when compared with heparin
bridging, showed a cost saving of $1800 per patient.
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2.3. Antithrombotic therapy in patients undergoing cardiac rhythm device implantation
Optimal management of antiplatelet therapy (AT) around CIED implantation is also chal‐
lenging. Medications used as AT (e.g., aspirin and clopidogrel) have long half-lives and no
efficient antidote; therefore, planning is essential to minimize the risk of bleeding while
keeping a low risk of thrombotic complication.
Tompkins et al. reported that dual antiplatelet therapy in patients undergoing pacemaker
implantation significantly increased frequency and severity of hemorrhagic complications,
compared with the use of aspirin alone [29]. Other authors found no increased risk of bleeding
complication in patients receiving clopidogrel or DAPT [30, 31].
ACC/AHA guidelines support continuing low-dose aspirin monotherapy for noncardiac
surgical procedures, noting only a small increase in procedure-related bleeding (relative risk
1.5). Management of dual AT or clopidogrel use is still a matter of debate. Yang et al. per‐
formed a meta-analysis to evaluate the effects of different antiplatelet combinations in pa‐
tients undergoing CIED surgery [1]. Dual antiplatelet therapy increased the risk of bleeding
largely during CIED implantations compared with control group (OR = 6.84, 95% CI 4.16–
11.25, P < 0.00001). Single antiplatelet therapy did not increase the risk of bleeding during
CIED implantations (OR = 1.52, 95% CI 0.93–2.46, P = 0.09). Single antiplatelet therapy with
clopidogrel increases the risk of hemorrhage when compared with aspirin (OR = 2.91, 95%
CI 1.27–6.69, P = 0.01).
Abbreviations
AF atrial fibrillation
ATE arterial thromboembolic events
APTT activated partial thromboplastin time
CIED cardiac implantable electronic device
OAC oral anticoagulation
NOAC novel anticoagulant
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